Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effectiviteits- en veiligheidsstudie van Tisagenlecleucel bij Braziliaanse patiënten met acute lymfoblastische leukemie of diffuus grootcellig B-cellymfoom

9 november 2026 bijgewerkt door: Novartis Pharmaceuticals

Effectiviteit en veiligheid van Tisagenlecleucel-therapie bij Braziliaanse patiënten met acute lymfoblastische leukemie of diffuus grootcellig B-cellymfoom: een 15-jarige prospectieve registratiestudie over twee cohorten

This will be a multicenter, national, non-interventional, prospective cohort study

Studie Overzicht

Gedetailleerde beschrijving

Eligible participants will be pediatric (<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisagenlecleucel through the commercial setting or out-of-specification (OOS) use in Brazil. We will collect data prospectively and complement missing information with retrospective data collection, when necessary. It is anticipated that approximately 200 patients will be enrolled in the cohort over 5 years divided among the study indications.

Since this is a non-interventional study, no administration of study drug or application of questionnaires will be mandated by this protocol. The study will consist of a "Pre-infusion" and a "Post infusion follow-up period" for up to 15 years post tisagenlecleucel infusion. All patients will be followed until death or last scheduled visit, whichever comes first.

For the study, "pre-infusion" and "follow-up post infusion" phases are defined as:

  • "Pre-infusion" will consist of the patient's information from the time of diagnosis untiljust prior to infusion with tisagenlecleucel.
  • "Follow-up Post infusion" information will comprise any information from the infusionof tisagenlecleucel onwards.

Studietype

Observationeel

Inschrijving (Geschat)

200

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Novartis Pharmaceuticals

Studie Locaties

      • São Paulo, Brazilië, 01509-010
        • Werving
        • Novartis Investigative Site
      • São Paulo, Brazilië, 01409-902
        • Werving
        • Novartis Investigative Site
    • Belo Horizonte
      • Minas Gerais, Belo Horizonte, Brazilië, 34006-059
        • Werving
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazilië, 41253-190
        • Werving
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brazilië, 81520-060
        • Werving
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brazilië, 01323-900
        • Werving
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brazilië, 04544-000
        • Werving
        • Novartis Investigative Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

1 seconde tot 100 jaar (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The study population will include pediatric/ adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia aged 0-25 years and adult patients aged ≥ 18 years with relapsed/refractory Diffuse Large B-cell Lymphoma and relapsed/refractory follicular lymphoma, who received tisagenlecleucel infusion in the commercial setting or out-of-specification.

Beschrijving

Inclusion Criteria:

Patients eligible for inclusion in this study must meet the following criteria:

  1. Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND

  2. Signed informed consent must be obtained prior to participation in study, AND

    For ALL participants:

  3. Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR

  4. Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR

    For DBLCL and FL participants:

  5. Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.

Exclusion Criteria:

  1. Patients who did not consent to data collection.
  2. Patients who received tisagenlecleucel infusion as part of any interventional clinical trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: OTHER

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Acute Lymphoblastic Leukemia (ALL)

Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Diffuse Large B-cell Lymphoma (DLBCL)

Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Follicular Lymphoma (FL)

Patients of any gender aged 18 year or older, with relapsed/refractory Follicular Lymphoma who received tisagenlecleucel infusion.

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall response rate (ORR)
Tijdsspanne: Up to 15 years

The overall response rate will be defined as the total proportion of participants exhibiting either the best overall response (BOR) of complete or partial responses and the proportion of patient with BOR of CR/PR or CR/CRi for ALL patients will be reported along with its 95% CI.

For ALL participants, the BOR will be defined as a CR or a CRi in accordance with National Comprehensive Cancer Network (NCCN) guidelines and previous guidelines (Appelbaum et al 2007)(Cheson et al 2003).

For lymphomas, the BOR will be defined as a CR or PR in accordance with the Cheson response criteria (Cheson et al 2007) and the Lugano classification (Cheson et al 2016).

Up to 15 years
MRD negative overall response rate
Tijdsspanne: Up to 15 years

The percentage of B-cell ALL patients who achieve a Best Overall Response (BOR) of CR or CRi with a Minimal residual disease (MRD) negative bone marrow will be provided with 95% CI.

Up to 15 years
Duration of overall response (DOR)
Tijdsspanne: Up to 15 years

Duration of overall response (DOR) applies only to patients whose best overall disease response was either:

  • CR or PR for patients with lymphomas, or
  • CR or a CRi for patients with ALL.

DOR will be defined as the time from the date of first documented disease response (Complete Response (CR) or PR for patients with lymphomas, and Complete Remission (CR) or CRi for patients with ALL), whichever occurs first, to the date of first documented progression or first documented relapse according to indication, or to the date of death due to the underlying disease.

In case a patient does not have progression/relapse or death due to underlying disease (defined as the event for this outcome) prior to data cut-off, DOR will be censored at the date of the last assessment on or prior to the earliest censoring event.

Up to 15 years
Relapse-free survival (RFS)
Tijdsspanne: Up to 15 years

RFS is measured by the time from date of first documented disease response as CR or CRi to relapse or death due to any cause in ALL patients.

In case a patient does not have relapse or death due to any cause prior to data cutoff, RFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event.

Up to 15 years
Event-free survival (EFS) for ALL patients
Tijdsspanne: Up to 15 years

EFS is the time from date of first tisagenlecleucel infusion to treatment failure, relapse or death from any cause, whichever occurred first, for B-cell ALL patients.

Up to 15 years
Progression free survival (PFS) for DLBCL patients
Tijdsspanne: Up to 15 years

PFS is defined as the time from the date of first infusion to the date of event defined as the first documented progression of lymphoma or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of the last adequate assessment.

In case a patient does not have progression or death prior to data cutoff, PFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event.

Up to 15 years
Overall survival (OS)
Tijdsspanne: Up to 15 years

Overall survival is the time from date of first tisagenlecleucel infusion to the date of death due to any reason, In case a patient is alive at the date of last contact on or before data cutoff, OS is censored at the date of last contact.

Up to 15 years
Number of ALL patients with hematologic recovery
Tijdsspanne: Up to 15 years

Dates of hematological recovery (i.e., dates of Absolute Neutrophil Count (ANC) and platelet recovery) will be collected.

ANC recovery is defined as an ANC of ≥ 0.5 × 109/L (500/mm^3) for 3 consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of 3 consecutive laboratory values where the ANC is ≥ 0.5 × 109/L (CIBMTR).

The first date of the 3 consecutive laboratory values obtained on different days where the platelet count was ≥ 20 × 109/L should be recorded. It should be ensured that no platelet transfusions were administered for 7 days immediately preceding this date (CIBMTR).

Up to 15 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The type and frequency of SAEs and AE of special interest
Tijdsspanne: Up to 15 years

The type and frequency of SAEs and AE of special interest (including secondary malignancies) will be collected

Up to 15 years
Incidence and severity of CRS and ICANS among HTLV 1 and 2 positive versus HTLV 1 and 2 negative patients
Tijdsspanne: Up to 15 years

Incidence and severity of Cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) among Human T-cell Lymphotropic Virus (HTLV) 1 and 2 positive versus HTLV 1 and 2 negative patients.

For CRS AE the protocol will follow the American Society of Transplant and Cellular Therapy (ASTCT) CRS Consensus Grading.

For ICANS AE the protocol will follow ASTCT consensus as well. Which establishes the Immune effector Cell-associated Encephalopathy (ICE Score) for adults/ adolescents and Cornell Assessment of Pediatric Delirium (CAPD) for pediatric patients under 12 years

Up to 15 years
Pregnancy rates
Tijdsspanne: Up to 15 years

Pregnancy rates will be collected

Up to 15 years
Number of patients with confirmed secondary malignancies diagnosis
Tijdsspanne: Up to 15 years

Number of patients with confirmed secondary malignancies diagnosis will be collected

Up to 15 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 november 2023

Primaire voltooiing (Geschat)

23 november 2037

Studie voltooiing (Geschat)

23 november 2037

Studieregistratiedata

Eerst ingediend

13 september 2022

Eerst ingediend dat voldeed aan de QC-criteria

13 september 2022

Eerst geplaatst (Werkelijk)

15 september 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren